Michael L O'Byrne1, Matthew J Gillespie. 1. Division of Cardiology, The Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Catheter-based valve technologies have evolved rapidly over the last decade. Transcatheter aortic valve replacement (TAVR) has become a routine procedure in high-risk adult patients with calcific aortic stenosis. In patients with congenital heart disease (CHD), transcatheter pulmonary valve replacement represents a transformative technology for right ventricular outflow tract dysfunction with the potential to expand to other indications. This review aims to summarize the current state-of-the-art for transcatheter valve replacement (TVR) in CHD; the expanding indications for TVR; and the technological obstacles to optimizing TVR. RECENT FINDINGS: Multiple case series have demonstrated that TVR with the Melody transcatheter pulmonary valve in properly selected patients is safe, effective, and durable in short-term follow-up. The Sapien transcatheter heart valve represents an alternative device with similar safety and efficacy in limited studies. Innovative use of current valves has demonstrated the flexibility of TVR, while highlighting the need for devices to address the broad range of postoperative anatomies either with a single device or with strategies to prepare the outflow tract for subsequent device deployment. SUMMARY: The potential of TVR has not been fully realized, but holds promise in treatment of CHD.
PURPOSE OF REVIEW: Catheter-based valve technologies have evolved rapidly over the last decade. Transcatheter aortic valve replacement (TAVR) has become a routine procedure in high-risk adult patients with calcific aortic stenosis. In patients with congenital heart disease (CHD), transcatheter pulmonary valve replacement represents a transformative technology for right ventricular outflow tract dysfunction with the potential to expand to other indications. This review aims to summarize the current state-of-the-art for transcatheter valve replacement (TVR) in CHD; the expanding indications for TVR; and the technological obstacles to optimizing TVR. RECENT FINDINGS: Multiple case series have demonstrated that TVR with the Melody transcatheter pulmonary valve in properly selected patients is safe, effective, and durable in short-term follow-up. The Sapien transcatheter heart valve represents an alternative device with similar safety and efficacy in limited studies. Innovative use of current valves has demonstrated the flexibility of TVR, while highlighting the need for devices to address the broad range of postoperative anatomies either with a single device or with strategies to prepare the outflow tract for subsequent device deployment. SUMMARY: The potential of TVR has not been fully realized, but holds promise in treatment of CHD.
Authors: Doff B McElhinney; William E Hellenbrand; Evan M Zahn; Thomas K Jones; John P Cheatham; James E Lock; Julie A Vincent Journal: Circulation Date: 2010-07-19 Impact factor: 29.690
Authors: Marko Vezmar; Rajiv Chaturvedi; Kyong-Jin Lee; Claudia Almeida; Cedric Manlhiot; Brian W McCrindle; Eric M Horlick; Lee N Benson Journal: JACC Cardiovasc Interv Date: 2010-04 Impact factor: 11.195
Authors: Silvia Schievano; Andrew M Taylor; Claudio Capelli; Louise Coats; Fiona Walker; Philipp Lurz; Johannes Nordmeyer; Sue Wright; Sachin Khambadkone; Victor Tsang; Mario Carminati; Philipp Bonhoeffer Journal: EuroIntervention Date: 2010-01 Impact factor: 6.534
Authors: Robert H Boone; John G Webb; Eric Horlick; Lee Benson; Qi-Ling Cao; N Nadeem; Marla Kiess; Ziyad M Hijazi Journal: Catheter Cardiovasc Interv Date: 2010-02-01 Impact factor: 2.692